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Abstract
Contributions of somatotropic hormonal activity to memory functions in humans, which are suggested by clinical
observations, have not been systematically examined. With previous experiments precluding a direct effect of systemic
growth hormone (GH) on acute memory formation, we assessed the role of central nervous somatotropic signaling in
declarative memory consolidation. We examined the effect of intranasally administered growth hormone releasing-
hormone (GHRH; 600 mg) that has direct access to the brain and suppresses endogenous GHRH via an ultra-short negative
feedback loop. Twelve healthy young men learned word-pair associates at 2030 h and were administered GHRH and
placebo, respectively, at 2100 h. Retrieval was tested after 11 hours of wakefulness. Compared to placebo, intranasal GHRH
blunted GH release within 3 hours after substance administration and reduced the number of correctly recalled word-pairs
by ,12% (both P,0.05). The impairment of declarative memory consolidation was directly correlated to diminished GH
concentrations (P,0.05). Procedural memory consolidation as examined by the parallel assessment of finger sequence
tapping performance was not affected by GHRH administration. Our findings indicate that intranasal GHRH, by
counteracting endogenous GHRH release, impairs hippocampal memory processing. They provide first evidence for a critical
contribution of central nervous somatotropic activity to hippocampus-dependent memory consolidation.
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Introduction
Studies in animals [1–3] and clinical observations in humans
[4–7] suggest that somatotropic axis activity benefits memory
function. However, little is known about the actual contribution of
growth hormone (GH) and its hypothalamic secretagogue, growth-
hormone releasing hormone (GHRH), to dissociable stages of
memory formation in humans [8,9]. Recent research has
highlighted the role of neuroendocrine secretion patterns associ-
ated with sleep in the consolidation of memories [10]. Secretory
activity of the somatotropic system shows a 24-hour maximum
during the first night-half in close temporal association with
episodes of slow-wave sleep that has been found to mediate
improving effects on the consolidation of declarative, hippocam-
pus-dependent memory contents (i.e., facts and episodes [11,12]).
Therefore, the release of GHRH and GH has been repeatedly
suspected to actively contribute to processes of memory consol-
idation [13,14]. However, blocking pituitary GH secretion in the
first half of nocturnal sleep by intravenous infusion of somatostatin
does not affect memory consolidation in healthy humans,
precluding a direct influence of systemic GH on acute memory
consolidation [15]. As circulating somatostatin does not cross the
blood-brain barrier (BBB), this finding leaves open that effects of
the somatotropic axis on declarative memory consolidation are
conveyed by GHRH. Here, we investigated in healthy humans the
effect of intranasal GHRH on declarative and procedural memory
consolidation. The intranasal route of administration was chosen




The study protocol conformed to the Declaration of Helsinki
and was approved by the ethics committee of the University of
Lu ¨beck. All participants gave written informed consent.
Subjects
We studied 12 healthy, right-handed young men aged 19 to 28
years (mean 6 SEM: 23.361.0 years) with a mean body mass
index between 20 and 25 kg/m
2 (23.560.5 kg/m
2). All subjects
had a regular self-reported sleep-wake cycle during the last four
weeks before the experiments as stated in pre-enrollment
interviews and abstained from caffeine and alcohol intake on
experimental days. Exclusion criteria were chronic or acute illness,
current medication of any kind, smoking and drug abuse.
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Subjects participated in two experimental conditions, GHRH
and placebo, according to a randomized and balanced cross-over
design. In the GHRH condition, subjects were intranasally
administered 600 mg GHRH1–44 (Bachem, Heidelberg, Germany)
dissolved in 6 ml saline solution. In the placebo condition saline
solution was administered. For administration, each subject
received two 100 ml nasal atomizer puffs (one per nostril) every
1 min over a period of 30 min. Subjects and experimenter were
blind with regard to the experimental condition. The two sessions
of an individual subject were separated by at least two weeks.
On experimental days, subjects arrived at the lab at 1930 h. For
blood sampling, a venous cannula was inserted into the subject’s
dominant arm. At 2030 h, subjects learned a list of word pairs for
declarative memory testing and learned a procedural memory task
(see below). From 2130–2200 h, GHRH and placebo were
administered depending on condition. The timing of GHRH
administration was chosen to cover the nocturnal period of
enhanced somatotropic activity. In order to exclude interfering
influences of sleep-related processes, subjects stayed awake
throughout the night, watching a standardized set of non-exciting
movies and playing non-verbal board games with the experiment-
er. Brisk physical activities were not allowed, and participants were
constantly monitored by the experimenter to ensure wakefulness.
They were allowed to drink water and were offered two light
snacks at 0000 h and 0615 h to exclude confounding effects of
increased hunger on cognitive measures. At 0900 h, i.e., after a
post-treatment consolidation interval of 11 hours, recall of word
pairs and procedural skill performance was tested. Heart rate and
blood pressure were monitored twice in the evening and twice in
the morning.
Memory tasks
To investigate the effects of GHRH on the consolidation of
declarative memory, a word pair interference paradigm was used
previously shown to be highly sensitive to experimental manipu-
lations of the consolidation process [19]. The task uses words
drawn from a pool of nouns matched for imageability, frequency
and concreteness that were randomly divided into three groups of
20 words, thus yielding three lists, A, B and C, with assignments to
lists B or C counterbalanced across participants. Each word in the
A list is paired with one word each from the B and C lists, thereby
forming two lists of paired associates: A–B and A–C (e.g., winter-
curd and winter-drawer). Parallel versions of the lists were used for
the two test sessions. At 2030 h (learning phase), participants
learned the first, i.e., A–B list of 20 word pairs. The word pairs
were presented in capital letters on a computer screen for 4 s each.
The whole list of word pairs was presented sequentially, in a fixed
order across subjects and conditions. Immediately afterwards,
participants were presented with the first (A) word of each pair and
were required to type the corresponding (B) word. The computer
provided immediate feedback by displaying the correct pairing for
4.5 seconds. Presentation of the list and immediate testing was
repeated until subjects correctly recalled 90% of the words. After a
post-treatment 11-hours retention period spent awake, subjects
learned the new, interfering list of word pairs (A–C) according to
the same training procedure as for the A–B list. After learning this
new list, subjects performed a 15-min distractor task to prevent
rehearsal between interference learning and final retrieval testing.
At retrieval, subjects were presented the first (A) words and asked
to recall the paired words from both lists, i.e., B and C of the A–B
and A–C lists. If subjects only remembered one of the two
completions, they were to leave the respective column blank.
Orthographical errors were counted as correct. Only those words
that were recalled and identified with the correct cue word (A) and
placed in the correct list (B column if learned before the retention
interval or C column if learned afterwards) were counted as
accurate. (The number of correctly recalled words placed in an
inappropriate list turned out to be negligible and was not further
analysed.) Thus the paradigm measures the extent to which the
memory for the A–B associations is weakened by interpolated
learning of the interfering A–C associations. Accordingly, the
primary outcome measure of consolidation was the difference
between the number of correctly remembered A–B associations at
retrieval and at learning.
Procedural memory was assessed using a finger sequence
tapping task (adopted from [20]) requiring subjects to press four
numeric keys on a standard computer keyboard with the fingers of
their left (non-dominant) hand, repeating the five-element
sequence as quickly and accurately as possible for a period of
30 seconds. The numeric sequence is displayed on the computer
screen at all times to exclude any working memory component to
the task. Each key press produces a white dot on the screen,
forming a row from left to right, rather than the numbers typed so
as not to provide accuracy feedback. Two motor patterns
containing completely unique grammars (4-1-3-2-4 and 2-3-1-4-
2) were used in a balanced order in the two experimental sessions.
The training session took place at around 2100 h, i.e., after the
study phase of the declarative memory task had ended, and
consisted of twelve 30-sec trials with 30-sec rest periods between
trials, lasting a total of 12 min. After the 11-hours post-treatment
retention period and after word pair retrieval testing, performance
on three trials of the finger sequence tapping task was probed.
Each 30-sec trial was scored for the number of complete sequences
achieved, designated as speed, and the number of correct
sequences, designated as accuracy. The averaged scores (speed
and accuracy) from the final three trials of the training sessions
were taken as baseline measures and scores from the respective
three 30-sec test trials were also averaged.
Mood and vigilance assessment
Self-reported mood was rated on 5-point scales covering the
categories good/bad mood, alertness/sleepiness and calmness/
agitation (MDBF [21]) before learning, after substance adminis-
tration and every 90 min thereafter with a final assessment taking
place before retrieval testing (0900 h). In parallel, hunger and
thirst were rated on 10-point scales. Sleepiness was assessed with
the Stanford Sleepiness Scale and, on these occasions, subjects also
performed a simple PC based vigilance task. In this task, a dot
(10 mm diameter) appeared every 2, 4, 6, 8 or 10 seconds in the
left or right field (randomly selected) of a computer screen and
subjects were required to press corresponding left and right keys as
fast as possible. Subjects received immediate feedback in the form
of the reaction time (in ms) after a correct response or the signal
‘Wrong!’ after an incorrect response. The task included 40 trials
(20 per screen half) and lasted approximately 5 min. For each 5-
min task, mean reaction time, error rate and the number of lapses
(reaction time .500 msec) were registered.
Blood sampling and assays
Blood was sampled for the determination of GH, adrenocor-
ticotropin (ACTH), cortisol, catecholamines, blood glucose and
insulin before substance administration (2025 and 2125 h) and
immediately thereafter at 2205 h. From 2215 h on, samples were
taken every 20 min until 2315 h, every 30 min until 0045 h and
every 60 min until 0845 h. A final sample was collected after
retrieval testing. Blood glucose was determined immediately after
sampling (HemoCue B-Glucose-Analyzer, A ¨ngelholm, Sweden).
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were frozen at 280uC for later analysis. Serum GH, cortisol and
insulin concentrations as well as plasma ACTH levels were
measured by commercial enzyme-linked immunoassays (all
Immulite, DPC, Los Angeles, CA, USA) with the following
intra-assay and inter-assay coefficients of variation (CV) and limits
of sensitivity (LOS), respectively: GH: ,5.8% and ,5.5%, LOS
0.05 mmol/l; cortisol: ,5.8% and ,6.3%, LOS 5.518 mmol/l;
insulin: ,5.2% and ,6.1%, LOS 12.0 pmol/l; ACTH: ,6.1%
and ,9.4%, LOS 0.4404 pmol/l. Plasma epinephrine and
norepinephrine were measured by standard high-performance
liquid chromatography with electrochemical detection (Chromo-
systems, Munich, Germany). Intra-assay and inter-assay CV was
,2.9% and ,4.2%, LOS 54.58 pmol/l for epinephrine and
,2.6% and ,3.9%, LOS 59.11 pmol/l for norepinephrine.
Statistical analyses
Values are expressed as means 6 SEM. Analyses were generally
based on analyses of variance (ANOVA) for repeated measures,
including the factors ‘treatment’ (for ‘GHRH’ vs. ‘placebo’) and
‘time’ (for repeated measurements during the session). Degrees of
freedom were corrected according to the Greenhouse-Geisser
procedure where appropriate. Single-time points comparisons
using two-tailed paired t-tests were calculated in case ANOVA
yielded significant treatment effects. A P-value less than 0.05 was
considered significant.
Results
Intranasal GHRH impairs declarative but not procedural
memory consolidation
Learning performance on the declarative memory task, i.e.,
word pair learning, was comparable between both learning
sessions (A–B list before the retention period and A–C interference
list before retrieval) and between conditions in terms of the
number of correct word pairs recalled during the criterion trial
(Figure 1A; GHRH vs. placebo, A–B: 19.3360.26 vs. 19.1760.24;
A–C: 19.0860.26 vs. 19.0960.25; all P.0.49) and of the number
of trials needed to reach the criterion of 90% correctly recalled
word pairs (A–B: 1.7560.13 vs. 2.0060.17; A–C: 2.0060.17 and
1.9160.21; all P.0.19).
Compared to the learning phase before the 11-hours retention
period, at the final retrieval test in the morning subjects
remembered distinctly less word pairs of the A–B list in both
conditions, reflecting in part the weakening effect on these
memories of interpolated learning of the A–C interference list
(F(1,11)=31.24, P,0.001 for Time). However, forgetting of A–B
associations was more pronounced after GHRH administration
(F(1,11)=5.47, P=0.039 for Treatment6Time). Accordingly,
the difference in correctly recalled word pairs from the A–B list
between learning and retrieval was greater in the GHRH
condition (Figure 1A; GHRH vs. placebo, 26.561.16 vs.
24.2560.99 word pairs, t=2.34, P=0.039; 65.9265.4% and
77.4566.24% of word pairs recalled at learning, t=2.21,
P=0.05). In contrast to the A–B list, retrieval of the A–C
interference list did not differ from learning performance and was
also comparable between both conditions (P.0.15 for all
comparisons; Figure 1A). Notably, in the GHRH condition,
retention of the A–B list (as indicated by the absolute difference in
correctly recalled word pairs between learning and retrieval) was
significantly correlated with plasma GH concentrations as assessed
by the area under the curve (AUC) 2200-0045 h (r=0.66,
P=0.019; Figure 1B). This correlation was not significant in the
placebo condition (r=0.36, P=0.244).
Finger sequence tapping performance was assessed with regard
to accuracy (number of correct sequences per trial) and speed
(number of sequences per trial). As the pattern of results was
similar for both measures, only accuracy measures are reported
here. During encoding before GHRH administration, task
performance significantly increased (Figure 1C; mean number of
sequences in the first three trials of encoding, GHRH vs. placebo,
11.1961.33 vs. 11.3661.08; in the last three trials, 15.5361.61 vs.
15.7561.31; F(1,11)=44.48, P,0.0001 for Time) with no
differences between conditions (F(1,11)=0.06, P=0.80 for
Treatment, (F(1,11)=0.006, P=0.80 for Treatment6Time).
Finger tapping performance did not change across the 11-h
retention interval and was also not influenced by GHRH
treatment (GHRH vs. placebo, 1.0560.63 vs. 20.560.91
sequences, F(1,11)=0.24, P=0.63 for Time, F(1,11)=2.12,
P=0.17 for Treatment6Time).
GHRH does not affect vigilance and tiredness while
improving subjective well-being
Subjects’ performance on the vigilance test deteriorated during
the night (P,0.01, for Time effects regarding reaction time, errors
and lapses), but was not affected by treatment (P.0.55 for
Treatment and Treatment6Time effects; Figure 2A). In
accordance, sleepiness assessed by the Stanford Sleepiness Scale
increased from baseline values at 2030 h (GHRH vs. placebo,
1.8360.21 vs. 1.7560.22) to reach maximum values at 0830 h
(4.8360.30 vs. 5.4260.27, P,0.001) but was not affected by
GHRH treatment (all P.0.54). Rated hunger and thirst were
likewise unaffected by GHRH administration (P.0.46, for all
comparisons). Subjective well-being as assessed by the MDBF
subscale ‘good/bad mood’ deteriorated during the night
(P,0.001). GHRH treatment attenuated this decrease and
improved mood in comparison to placebo values (F(3,35)=3.39,
P,0.03 for Treatment6Time), yielding significantly higher
values towards the end of the session (Figure 2B). Mood
improvement after intranasal GHRH was not related to the
deterioration of declarative memory consolidation in this condi-
tion (P.0.15 for all correlations between mood ratings at 0830 h
and 0900 h and measures of memory retrieval).
Intranasal GHRH reduces GH secretion
During baseline before substance administration, circulating
hormone concentrations and blood glucose levels were closely
comparable between conditions (all P.0.38). Circulating GH
concentrations that showed a small but distinct GH peak in the
control condition during the first night half were markedly reduced
by intranasal GHRH administration (Figure 3; F(1,11)=10.18,
P,0.009 for Treatment, P=0.16 for Treatment6Time). Ac-
cordingly, area under the curve (AUC) analyses covering the first
three hours after GHRH administration, i.e., a time interval when
based on previous observations maximal treatment effects were to
be expected [12,16,22], indicated distinctly blunted GH plasma
concentrations following GHRH as compared to placebo
administration (56.70621.15 vs. 201.04665.12 mg/l*min,
P=0.046). Likewise, individual GH peak values reached during
this time period were markedly smaller in the GHRH condition
(1.8960.67 vs. 6.5761.88 mg/l, P=0.022). Thereafter, GH
concentrations did not differ between conditions.
Blood glucose concentrations (P.0.31 for respective Treatment
and Treatment6Time effects) as well as circulating concentra-
tions of insulin (P.0.22), ACTH (P.0.15), cortisol (P.0.70),
epinephrine (P.0.36) and norepinephrine (P.0.54) were not
affected by treatment. Across conditions, ACTH and cortisol
showed the expected circadian increase in the second night half
GHRH Signaling in Declarative Memory Consolidation
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23435Figure 1. GHRH impairs declarative memory consolidation. (A) Declarative memory: Mean (6 SEM) performance on the word pair
interference task as assessed by the number of correctly recalled word pairs in the GHRH condition (black bars; intranasal administration of 600 mg
GHRH1–44 from 2130–2200 h) and the placebo condition (white bars; vehicle). Encoding of the A–B word pair list (plain bars) took place before
substance administration and a nocturnal retention interval of 11 hours spent awake. Encoding of the A–C word pair list (hatched bars) took place
after the retention interval. Retrieval of both lists was jointly tested at the end of the session. GHRH administration significantly reduced retention of
A–B word pairs whereas retrieval of the A–C interference list remained unaffected. * P,0.05. (B) Retention of word pairs in the GHRH condition
plotted against respective 2200-0045 h plasma GH AUC values, indicating a positive correlation between consolidation of word pairs and post-
learning somatotropic activity (r=0.66, P=0.019; note that excluding the subject with the highest plasma GH AUC value from analysis yielded
essentially the same result, r=0.61, P=0.046). (C) Procedural memory: Mean (6 SEM) finger tapping performance indicated by the number of correct
sequences within a 30 sec trial during encoding and after the retention interval following intranasal administration of GHRH (black dots, solid lines)
and vehicle (white dots, dashed lines), respectively. Encoding consisted of twelve 30-sec trials and retrieval testing comprised three 30-sec trials.
Unlike declarative word pair memories, procedural finger tapping skill was not affected by GHRH. N=12.
doi:10.1371/journal.pone.0023435.g001
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unaffected by GHRH treatment (all P.0.22). Interviews at the
end of the sessions confirmed that subjects could not correctly
indicate if they had received placebo or GHRH (P=0.41, chi-
square test).
Discussion
GHRH administered intranasally following the acquisition of
two memory tasks impaired consolidation of declarative but not
procedural memory. GHRH also decreased plasma GH concen-
trations between 1–2 hours post-administration as reflected by the
complete blunting of a peak in GH release emerging during the
nocturnal retention period in the placebo condition. In combina-
tion, both effects support the view that inhibiting somatotropic
activity at the central nervous level impairs the acute consolidation
of declarative, i.e., hippocampus-dependent memory traces.
The inhibition of GH secretion from the pituitary by intranasal
GHRH administration is seemingly paradoxical. However, it
replicates previous results indicating that intranasal GHRH
Figure 2. Vigilance and mood after GHRH and placebo administration. Mean (6 SEM) (A) reaction times in a PC based vigilance task and (B)
ratings of subjective well-being as derived from the ‘good/bad mood’ subscale of the MDBF questionnaire (with high values indicating good mood
[21]) during the nocturnal retention period spent awake following intranasal administration of 600 mg GHRH1–44 (black dots, solid lines) and vehicle
(white dots, dashed lines), respectively. Periods of substance administration and encoding/retrieval of the memory tasks are indicated. N=12,
t p,0.10, * P,0.05.
doi:10.1371/journal.pone.0023435.g002
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with early nocturnal sleep [22]. Here, because our subjects were
awake to exclude interfering influences of sleep-related processes,
the early nocturnal GH peak was distinctly smaller [23,24].
Nevertheless, it was entirely blunted by intranasal GHRH. In rats,
the intracerebroventricular injection of low doses of GHRH
likewise reduces pituitary GH release [25]. The suppressing effect
of intranasal GHRH on pituitary GH secretion can thus be
explained by exogenous GHRH activating an ultra-short negative
feedback mechanism on endogenous, hypothalamic GHRH
secretion [26]. According to in vitro-studies, this feedback-
suppression of somatotropic activity may involve activation of
somatostatin releasing neurons [27]. On the background of
reduced instead of enhanced pituitary GH secretion, peripheral
effects of intranasal GHRH can be safely excluded. Also, previous
studies have demonstrated unchanged GHRH levels in plasma
after intranasal administration of the compound [28].
The central finding of our study indicates impaired consolida-
tion of hippocampus-dependent declarative memory by intranasal
GHRH administered after the learning period. GHRH adminis-
tration made the word pair associations acquired before substance
administration more vulnerable to the disturbing influence of
associative interferences learned shortly before retrieval testing. A
persisting effect of GHRH immediately acting on retrieval
function can be excluded because immediate recall of the
interfering word list newly acquired at the time of the final
retrieval test was completely unaffected. Experiments were
conducted during nocturnal wakefulness to differentiate purely
somatotropic from sleep-related influences on memory consolida-
tion, which, on the other hand, limits the transfer of our results to
the regular sleep setting. GHRH administered via the intravenous
[29] but also the intranasal route [22] has moderate sleep-
enhancing properties, mainly on slow wave sleep [26,30]. Our
finding of comparable vigilance and sleepiness measures in both
conditions is consistent with the observation that any sleep-
promoting effect of GHRH is particularly small at times of high
sleep propensity (i.e., late evening [31]). On the other hand, it
excludes a biasing influence of sleepiness on recall performance.
Also, improved mood in the GHRH as compared with the placebo
condition was unrelated to the deterioration of memory consol-
idation due to GHRH administration.
The impairing influence of intranasal GHRH was specific to
the consolidation of declarative word pairs. Procedural finger
sequence tapping performance in both conditions reached a post-
training level lower than in some [32,33] but not all comparable
previous studies [34,35] where tapping performance nevertheless
showed the typical sleep-dependent improvement. In contrast to
word pair consolidation, results of the finger sequence task
remained completely unaffected by GHRH administration.
Processing of declarative memory requires the involvement of
hippocampal structures [36,37]. Endogenous somatotropic activity
reaches a maximum during the early night-half in close temporal
association with the first periods of nocturnal slow wave sleep that
has been demonstrated to support preferentially the consolidation
of hippocampus-dependent memory [12,38,39]. Against the
background of the well-known slow wave sleep-promoting
properties of GHRH administration [26,30], those findings
stimulated the assumption that somatotropic axis activity facilitates
memory formation [13,14]. In accordance, clinical studies on the
subchronic administration of GH and GHRH in GH-deficient
humans and in healthy older adults have revealed some evidence
that somatotropic hormones are involved in the long-term
maintenance of memory systems [4–7]. Recent animal data
indicate that repetitive injections of GH can alleviate the impairing
effects of prolonged sleep deprivation on hippocampal N-methyl-
D-aspartate (NMDA) glutamate receptor function [2]. However,
Figure 3. Intranasal GHRH decreases circulating GH concentrations. Mean (6 SEM) serum concentrations of GH during nocturnal
wakefulness following intranasal administration of 600 mg GHRH1–44 (black dots, solid line) and placebo (white dots, dashed line), respectively.
Administration of GHRH and placebo took place after encoding of declarative and procedural memory tasks that were retrieved 11 hours later after
encoding of an interference word pair list. N=12, * P,0.05.
doi:10.1371/journal.pone.0023435.g003
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investigating the effects of somatotropic activity on the retention
of specific memory contents [15]. In that study, post-learning
inhibition of pituitary GH release by somatostatin infusion
abrogated the early nocturnal GH peak but failed to affect
sleep-associated consolidation of memory for word pairs learned in
the preceding evening. Importantly, to reduce GH secretion,
intravenous somatostatin acts on the pituitary that is located
outside of the BBB, but it does not pass the BBB [40,41]. Thus,
any significant contribution of peripheral GH to sleep-related
declarative memory processing was ruled out. In conjunction with
those findings, the present data identify brain-borne GHRH as the
factor conveying the influence of somatotropic axis activity on the
consolidation of hippocampus-dependent memories: The inhibi-
tion of somatotropic activity at the central nervous level, via
activation of ultra-short negative feedback induced by intranasal
GHRH, but not by somatostatin acting at the pituitary, impairs
declarative memory consolidation. This assumption is further
buttressed by the significant correlation between declarative
memory retrieval and circulating GH levels, which directly reflect
central nervous GHRH secretion, that emerged in the GHRH
condition and suggests that somatotropic and cognitive treatment
effects were strongly linked. In the placebo condition, saturation
due to higher central nervous GHRH levels might have prevented
that slight variations in GHRH levels manifested themselves in
corresponding variations in memory performance.
One plausible scenario accounting for the central nervous
memory effects of GHRH assumes a direct action of the peptide
on memory related brain structures. GHRH is predominantly
produced in the arcuate nucleus of the hypothalamus with
projections to the median eminence. Projections between
hypothalamic and hippocampal structures are well documented
[42,43] and GHRH has been traced in extrahypothalamic regions
including amygdala, hippocampus and cortical regions [44–47]
where it probably acts as a neurotransmitter and/or neuromod-
ulator [45,48]. Interestingly, ghrelin that stimulates pituitary GH
via GHRH-dependent pathways [49] and shares receptor
mechanisms with GHRH [50] has been shown to bind to
hippocampal neurons, promoting dendritic spine synapse density
and spatial memory [51,52], which tempts to speculate that
GHRH exerts comparable hippocampal effects. In addition,
endogenous GHRH might improve memory processing by
enhancing central nervous GH and IGF-1 signaling [53,54] that
can promote declarative memory by inducing gene expression for
hippocampal glutamatergic NMDA receptors [1,3,53,55].
In sum, this is the first study to show that central nervous
GHRH is involved in the consolidation of declarative memories by
demonstrating that intranasal GHRH administration, by a
presumptive immediate negative feedback action on central
nervous GHRH networks, makes declarative memory contents
more vulnerable to interfering influences. Our findings support the
notion that somatotropic axis activity, which is most prominent
during early sleep, contributes to the consolidation of hippocam-
pus-dependent memories by enhanced GHRH feed forward
signaling.
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